Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 19, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes and Transactions
- April 13, 2006: The GSK Trust transferred 48,000 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- April 17, 2006: The GSK Trust sold 1,025 ADSs on behalf of participants in the SmithKline Beecham Mid-Term Incentive Plan at a price of $52.40 per ADS.
- April 17, 2006: The GSK Trust transferred 2,193 ADSs to participants in the SmithKline Beecham Mid-Term Incentive Plan.
Management Commentary and Risks
The GSK Trust is a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. Three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold interests in the shares held by the GSK Trust in the same capacity as other employees. The filing notes that the company was advised of these transactions on April 18, 2006, and they were notified in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Checklist
- Verify the total number of shares transferred to employee incentive plans during the reporting period.
- Confirm the sale price of $52.40 per ADS against market prices on April 17, 2006.
- Review the specific terms of the SmithKline Beecham Employee Share Option Plan 1991 and Mid-Term Incentive Plan.
- Check for any subsequent filings regarding the directors' interests in the GSK Trust.